FDA Clears Inhaled Insulin Afrezza
Soon there will be a new way to take premeal insulin: Inhale it. The U.S. Food and Drug Administration has cleared Afrezza, an inhaled rapid-acting insulin for adults with type 1 and type 2 diabetes. (The drug is not recommended for smokers or people with chronic lung disease.) Afrezza seems to work faster than injected rapid-acting insulin. The manufacturer, MannKind Corp., is hopeful Afrezza will succeed where the more expensive inhaled insulin Exubera failed. Afrezza has a smaller, easier-to-use inhaler than Exubera did and is expected to cost about as much as insulin pens. However, injections are still the only option for long-acting insulin.
Source: American Diabetes Association's 74th annual Scientific Sessions, June 2014.